Skip to main content
The NCI Community Hub will be retiring in May 2024. For more information please visit the NCIHub Retirement Page:

Overview of the National Cancer Institute (NCI) Nanotechnology Characterizaton Laboratory (NCL)

By Jennifer Hall Grossman

Frederick National Laboratory for Cancer Research

Download (PDF)

Licensed according to this deed.

Published on


Working in concert with the National Institute of Standards and Technology (NIST) and the U.S. Food and Drug Administration (FDA), the National Cancer Institute (NCI) established the Nanotechnology Characterization Laboratory to perform preclinical efficacy and toxicity testing of nanoparticles.

The NCL serves as a national resource and knowledge base for all cancer researchers to facilitate the regulatory review of nanotechnologies intended for cancer therapies and diagnostics. By providing the critical infrastructure and characterization services to nanomaterial providers, the NCL accelerates the transition of basic nanoscale particles and devices into clinical applications, thereby reducing suffering and death from cancer.

As part of its assay cascade, the NCL characterizes nanoparticles' physical attributes, their in vitro biological properties, and their in vivo compatibility using animal models. The time required to characterize nanomaterials from receipt through the in vivo phase is approximately one year.

Cite this work

Researchers should cite this work as follows:

  • Jennifer Hall Grossman (2014), "Overview of the National Cancer Institute (NCI) Nanotechnology Characterizaton Laboratory (NCL),"

    BibTex | EndNote


Mervi Heiskanen

National Cancer Institute